Levomilnacipran as a medication for depression - discussion
Levomilnacipran (brand name Fetzima) is an antidepressant approved for the treatment of major depressive disorder in the United States. It was developed by Forest Laboratories and Pierre Fabre Group, and was approved by the Food and Drug Administration in July 2013. Levomilnacipran is the levo- enantiomer of milnacipran, and has similar effects and pharmacology, acting as a serotonin-norepinephrine reuptake inhibitor (SNRI). More: en.wikipedia.org.
0 opinions, 0 replies
Add your opinion:
Challenge someone to answer this topic:
Invite an OpiWiki user:
OR
Invite your friend via email:
@
click for template
OR
Share it:
Share this discussion via OpiWiki smartlink:
OR